These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 26477469)

  • 1. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 5. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immuno-Oncology therapeutic principles in lung and renal cell carcinoma].
    Wolf J; Grünwald V
    Oncol Res Treat; 2014; 37 Suppl 4():10-3. PubMed ID: 25301191
    [No Abstract]   [Full Text] [Related]  

  • 7. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status.
    Chandrakanth MV; Noronha V; Joshi A; Patil V; Mahajan A; Prabhash K
    Indian J Cancer; 2017; 54(1):55-56. PubMed ID: 29199664
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
    Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
    Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the immune system for the treatment of non-small-cell lung cancer.
    Brahmer JR
    J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for non-small cell lung cancer.
    Reckamp KL
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-oncology moves beyond PD-1.
    Sheridan C
    Nat Biotechnol; 2015 Jul; 33(7):673-5. PubMed ID: 26153987
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 17. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PD-L1 for non-small-cell lung cancer.
    Feld E; Horn L
    Immunotherapy; 2016 Jun; 8(6):747-58. PubMed ID: 27197542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Immune Therapy-Implications for Pathologists.
    Miller RA; Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
    [No Abstract]   [Full Text] [Related]  

  • 20. Chinese scientists to pioneer first human CRISPR trial.
    Cyranoski D
    Nature; 2016 Jul; 535(7613):476-7. PubMed ID: 27466105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.